Coloplast, a Danish multinational company that develops, manufactures and markets medical devices and services, completed the acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder, for $145m. "I am excited about the prospects of the Nine Continents device and pleased to confirm our commitment to the Interventional Urology business with this acquisition in the large OAB market. There is a large group of patients in the US and abroad suffering from OAB, and with Nine Continents’ innovative, minimally invasive device we hope to help these people live a better life," Kristian Villumsen, Coloplast President and CEO.